Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$1.76
-6.4%
$1.69
$1.21
$3.81
$43.47M0.68259,323 shs137,214 shs
Biomerica, Inc. stock logo
BMRA
Biomerica
$3.18
+2.3%
$3.95
$1.93
$10.16
$7.92M0.37275,803 shs15,550 shs
Celularity Inc. stock logo
CELU
Celularity
$2.38
+3.9%
$1.75
$1.00
$5.22
$57.00M0.61333,567 shs47,410 shs
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.36
+3.0%
$1.20
$0.89
$4.29
$58.33M0.85256,258 shs107,927 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00%0.00%+21.38%-33.33%-4.35%
Biomerica, Inc. stock logo
BMRA
Biomerica
+2.25%-12.64%-18.04%-46.79%-36.50%
Celularity Inc. stock logo
CELU
Celularity
+3.93%+2.15%+47.83%+73.72%-31.21%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
+3.03%-0.73%+8.80%+8.80%-56.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.5332 of 5 stars
1.00.00.00.00.63.31.3
Biomerica, Inc. stock logo
BMRA
Biomerica
0.2518 of 5 stars
0.03.00.00.01.90.80.0
Celularity Inc. stock logo
CELU
Celularity
0.0619 of 5 stars
0.00.00.00.01.81.70.0
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
3.1057 of 5 stars
3.35.00.00.02.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
2.00
Hold$1.67-5.30% Downside
Biomerica, Inc. stock logo
BMRA
Biomerica
0.00
N/AN/AN/A
Celularity Inc. stock logo
CELU
Celularity
0.00
N/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.50
Moderate Buy$4.50230.88% Upside

Current Analyst Ratings Breakdown

Latest BMRA, AADI, CELU, and RPTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/7/2025
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $5.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M1.73N/AN/A$4.29 per share0.41
Biomerica, Inc. stock logo
BMRA
Biomerica
$5.68M1.43N/AN/A$0.39 per share8.15
Celularity Inc. stock logo
CELU
Celularity
$54.22M1.05$9.92 per share0.24$2.11 per share1.13
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.07M54.36N/AN/A$5.03 per share0.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)
Biomerica, Inc. stock logo
BMRA
Biomerica
-$5.98M-$2.32N/AN/A-100.52%-90.19%-64.54%N/A
Celularity Inc. stock logo
CELU
Celularity
-$196.29M-$2.65N/AN/A-72.72%-119.53%-25.40%7/28/2025 (Estimated)
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$93.80M-$3.01N/AN/AN/A-99.76%-40.87%-35.07%N/A

Latest BMRA, AADI, CELU, and RPTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q4 2024
Celularity Inc. stock logo
CELU
Celularity
-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million
4/14/2025Q3 2025
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A-$0.48N/A-$0.06N/A$1.12 million
3/18/2025Q4 2024
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$0.30-$0.67-$0.37-$0.67$7.45 million$7.24 million
3/3/2025Q4 2024
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$0.77-$0.67+$0.10-$0.67$0.67 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Biomerica, Inc. stock logo
BMRA
Biomerica
N/AN/AN/AN/AN/A
Celularity Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A
3.17
2.22
Celularity Inc. stock logo
CELU
Celularity
N/A
0.19
0.14
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/A
6.45
6.45

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Biomerica, Inc. stock logo
BMRA
Biomerica
22.28%
Celularity Inc. stock logo
CELU
Celularity
19.02%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
85.09%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Biomerica, Inc. stock logo
BMRA
Biomerica
15.00%
Celularity Inc. stock logo
CELU
Celularity
22.10%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
11.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionOptionable
Biomerica, Inc. stock logo
BMRA
Biomerica
602.55 million15.59 millionOptionable
Celularity Inc. stock logo
CELU
Celularity
22023.95 million18.55 millionOptionable
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
18042.89 million33.33 millionOptionable

Recent News About These Companies

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds
Repare Therapeutics Names Forte as President, CEO
Repare Therapeutics Announces Leadership Transitions
Repare Therapeutics Reduces Workforce by 75 Percent
Repare Therapeutics reports Q4 EPS (67c), consensus (79c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$1.76 -0.12 (-6.38%)
As of 05/23/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Biomerica stock logo

Biomerica NASDAQ:BMRA

$3.18 +0.07 (+2.25%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.21 +0.03 (+0.91%)
As of 07:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Celularity stock logo

Celularity NASDAQ:CELU

$2.38 +0.09 (+3.93%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.37 -0.01 (-0.63%)
As of 05/27/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Repare Therapeutics stock logo

Repare Therapeutics NASDAQ:RPTX

$1.36 +0.04 (+3.03%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.37 +0.01 (+0.74%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.